| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/22/2009 | CN100516024C Amino-propanol derivatives |
| 07/22/2009 | CN100516018C Double esters |
| 07/22/2009 | CN100515497C Liposomal delivery of vitamin E based compounds |
| 07/22/2009 | CN100515495C Lyophilized preparation containing antibodies to the EGF receptor |
| 07/22/2009 | CN100515422C Composition containing benzamidine derivative and method for stabilizing benzamidine derivative |
| 07/22/2009 | CN100515419C Substituted benzazoles and its application as inhibitors of Raf kinase |
| 07/22/2009 | CN100515416C A herbal molecule as potential anti-leukemic drug |
| 07/21/2009 | US7563913 Compound and pharmaceutical composition |
| 07/21/2009 | US7563893 3-Phenyl-cinnoline analogue and antitumor agent using the same |
| 07/21/2009 | US7563884 Antisense modulation of PTP1B expression |
| 07/21/2009 | US7563882 Comprises polypeptide for diagnosis and treatment of tumors; immunotherapy |
| 07/21/2009 | US7563876 For binding and blocking human mannose receptors; fibronectins; immunoglobulins; cd antigens; cytolysis; cytotoxic lymphocytes; for treatment of automimmune diseases |
| 07/21/2009 | US7563824 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 07/21/2009 | US7563820 Administering strylacrylonitrile compound; antiproliferative agents; anticancer agents |
| 07/21/2009 | US7563819 Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| 07/21/2009 | US7563798 3-(1-Methyl-pyrazol-4-yl-),4-Piperidino,7-((3-Methyl-isothiazol-5-yl)-pyrazolo(1,5-a) pyrimidine; cyclin dependent kinase inhibitors; anticarcinogenic agents; antiinflammatory agents; antiarthritic agents; viricides; neurodegenerative diseases; Alzheimer's disease;cardiovascular diseases; fungicides |
| 07/21/2009 | US7563790 Pyridazine derivatives |
| 07/21/2009 | US7563781 Such as 1-dimethylamino-3-[4-(3-indan-5-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-ylamino)-phenoxy]-propan-2-ol; serine-tyrosine and tyrosine kinase inhibitors; cancer, metastasis |
| 07/21/2009 | US7563778 Antisense oligonucleotide preparation method |
| 07/21/2009 | US7563765 Histidine-rich glycoprotein |
| 07/21/2009 | US7563760 P-selectin ligand protein |
| 07/21/2009 | US7563593 Harvesting, separating, culturing and exposing tissue to antiproliferative agents, monitoring variation in tissue propagation; immunotherapeutics; wound healing agents |
| 07/21/2009 | US7563582 Identifying chemical compounds which are capable of modulating the interaction between vasodilator-stimulated phosphoprotein and zyxin |
| 07/21/2009 | US7563459 Administering a glycoconjugated asialoorosomucoid and the stem cell to the mammal for drug delivering to a target tissue; regenerating heart tissue; tissue-targeted therapy, gene therapy |
| 07/21/2009 | US7563450 UL16 binding protein 4 |
| 07/21/2009 | US7563445 Tumor antigens/vaccines such as cytotoxic T-lymphocytes (CTL) |
| 07/21/2009 | US7563442 Antibodies to CD40 and methods of treating cancer and enhancing immune responses |
| 07/21/2009 | CA2470809C 6-amino-morphinan derivatives, method of manufacturing them and their application |
| 07/21/2009 | CA2406650C Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites |
| 07/21/2009 | CA2404548C 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses |
| 07/21/2009 | CA2387486C Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 07/21/2009 | CA2386423C Pharmaceutical compositions containing copper, salicylic acid and vitamines c |
| 07/21/2009 | CA2379972C Prodrug of an ice inhibitor |
| 07/21/2009 | CA2328528C Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody |
| 07/21/2009 | CA2201310C Antineoplastic cocoa extracts and methods for making and using the same |
| 07/16/2009 | WO2009089537A2 Anti-cancer compounds |
| 07/16/2009 | WO2009089502A1 Inhibitors of iap |
| 07/16/2009 | WO2009089462A1 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| 07/16/2009 | WO2009089461A1 Plexind1 agonists and their use |
| 07/16/2009 | WO2009089459A1 Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 07/16/2009 | WO2009089454A1 Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 07/16/2009 | WO2009089453A1 Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
| 07/16/2009 | WO2009089383A2 Inhibitors of carbonic anhydrase ix |
| 07/16/2009 | WO2009089359A1 Pyrazolopyridines as kinase inhibitors |
| 07/16/2009 | WO2009089352A1 Pyrrolopyridines as kinase inhibitors |
| 07/16/2009 | WO2009089338A2 Method and compositions for administering resveratrol and pterostilbene |
| 07/16/2009 | WO2009089260A2 Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| 07/16/2009 | WO2009089237A1 Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as beta-amyloid inhibitors |
| 07/16/2009 | WO2009089186A2 Peptide-conjugated oligonucleotide therapeutic and method of making and using same |
| 07/16/2009 | WO2009089149A1 B7-h1 (cd274) antagonists induce apoptosis of tumor cells |
| 07/16/2009 | WO2009089147A2 Methods and compositions for the treatment of cancers and pathogenic infections |
| 07/16/2009 | WO2009089138A1 Oral administration of ixabepilone |
| 07/16/2009 | WO2009089042A1 Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
| 07/16/2009 | WO2009088992A2 Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer |
| 07/16/2009 | WO2009088854A1 Epoxy-guaiane derivatives and treatment of cancer |
| 07/16/2009 | WO2009088838A2 Triarylmethane analogs and their use in treating cancers |
| 07/16/2009 | WO2009088837A2 Methods and products to target, capture and characterize stem cells |
| 07/16/2009 | WO2009088831A2 Method of inhibiting abcg2 and other treatment methods |
| 07/16/2009 | WO2009088518A1 A2b adenosine receptor antagonists for the treatment of cancer |
| 07/16/2009 | WO2009087988A1 Composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy |
| 07/16/2009 | WO2009087978A1 Anti-cldn6 antibody |
| 07/16/2009 | WO2009087381A1 Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| 07/16/2009 | WO2009087368A1 Compositions comprising ganoderma lucidum extracts and uses thereof |
| 07/16/2009 | WO2009087305A1 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors |
| 07/16/2009 | WO2009087238A2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies |
| 07/16/2009 | WO2009087173A2 Antibody designated barb3, barb3 related antibodies, and methods of making and using same |
| 07/16/2009 | WO2009087130A1 Use of a gamma-secretase inhibitor for treating cancer |
| 07/16/2009 | WO2009086920A1 Anti mif antibodies |
| 07/16/2009 | WO2009086835A1 Novel cyanoguanidines |
| 07/16/2009 | WO2009086731A1 New benzimidazole compounds |
| 07/16/2009 | WO2009086720A1 2,3,4,6-tetra-o-acetyl-d-glucopyranosyl-[n,n'-di-(2-chloroethyl)]-phosphoric acid diamide, preparation methods and uses thereof |
| 07/16/2009 | WO2009086656A1 Y-type polyethylene glycol modified g-csf and preparation method and use thereof |
| 07/16/2009 | WO2009086640A1 Adjuvant compositions comprising poly-ic and a cationic polymer |
| 07/16/2009 | WO2009067686A8 Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof |
| 07/16/2009 | WO2009065946A3 Pharmaceutical kit consisting of an oil-in-water emulsion and a solid composition |
| 07/16/2009 | WO2009065090A3 Pharmaceutical compositions for the treatment of conditions responsive to proteasome inhibition |
| 07/16/2009 | WO2009064738A9 Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| 07/16/2009 | WO2009064486A9 Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| 07/16/2009 | WO2009059984A3 Reversible hydrophobization of antitumor drugs for enhanced first-pass drug uptake |
| 07/16/2009 | WO2009053064A8 Sdf-1-based glycosaminoglycan antagonists and methods of using same |
| 07/16/2009 | WO2009046860A3 Use of dago as a therapeutic agent |
| 07/16/2009 | WO2009046859A3 Use of af12198 and dago as therapeutic agents |
| 07/16/2009 | WO2009040778A3 Pharmaceutical compositions containing the enzyme cyprosin, an aspartic peptidase from cynara cardunculus and its inclusion in antitumour formulations |
| 07/16/2009 | WO2009040035A3 Use of a peptide as a therapeutic agent |
| 07/16/2009 | WO2009039990A3 Use of icam peptide as a therapeutic agent |
| 07/16/2009 | WO2009039974A3 Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 07/16/2009 | WO2009037539A3 Treatment of oestrogen dependant conditions in pre-menopausal women |
| 07/16/2009 | WO2009033817A3 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent |
| 07/16/2009 | WO2009033766A3 Use of a peptide as a therapeutic agent |
| 07/16/2009 | WO2009024103A3 Natural brassinosteroids for use for treating hyperproliferation, treating proliferative diseases and reducing adverse effects of steroid dysfunction in mammals, pharmaceutical composition and its use |
| 07/16/2009 | WO2009003999A3 Chemical compounds |
| 07/16/2009 | WO2008147562A3 Dietary formulations and methods for treatment of inflammation and other disorders |
| 07/16/2009 | WO2008128169A8 Sparc and methods of use thereof |
| 07/16/2009 | WO2008121016A8 Oncological disease treating method |
| 07/16/2009 | WO2008109454A8 Nucleic acid compounds for inhibiting fos gene expression and uses thereof |
| 07/16/2009 | WO2008094942A8 Humanized antibodies against cxcr3 |
| 07/16/2009 | WO2008068171A9 Substituted pyrimidines and their use as jnk modulators |
| 07/16/2009 | WO2008015383A8 Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies |
| 07/16/2009 | WO2007098611A8 Compositions for treatment of cancer |
| 07/16/2009 | WO2002087497A3 Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use |